Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency
Glossary on
off
Printer Friendly Page TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

Clinicaltrials.gov identifier:
NCT03395197


Study Contact Information:

For more information about the study,
visit www.pfizerclinicaltrials.com/talapro2

TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

About the Study

TALAPRO-2 is a study for men who have been diagnosed with castration-resistant cancer (mCRPC) which means that hormone therapies, one of the main treatment options for this type of cancer, have no effect and the tumor has spread to other parts of the body. NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.